key: cord-1002499-3rbb9lau authors: Desai, Anish K.; Hodovan, James; Belcik, J. Todd; Lindner, Jonathan R. title: HYPERSENSITIVITY CROSS-REACTIVITY FOR ULTRASOUND ENHANCING AGENTS AND COVID-19 VACCINES date: 2022-02-16 journal: J Am Soc Echocardiogr DOI: 10.1016/j.echo.2022.02.006 sha: 8b32ce86c994c6a28eaeb6f3c782b6fb14e1b327 doc_id: 1002499 cord_uid: 3rbb9lau nan safety recommendations for PEG-containing UEAs, and highlighted that the MedWatch report did not change information on the incidence of serious AEs. 5 Yet anecdotal reports have raised concern that hypersensitivity reactions to UEAs may have increased after the introduction of COVID-19 vaccines. 6 While it is possible that exposure to PEGylated lipid vaccines could increase type-I hypersensitivity to UEAs or CARPA, 7 scientific evidence is lacking and was the aim of this study. According to power calculations, a prospective study powered at 0.90 to detect a 5-fold J o u r n a l P r e -p r o o f increase in severe AEs to UEAs (=0.05) based on vaccination status would require a study size of 80,000 subjects. Because of the urgency of the question, we instead examined cross-reactivity through a retrospective survey to assess for mRNA vaccine hypersensitivity in patients exposed to The aim of this study was to examine whether a link exists between hypersensitivity reactions to lipid-based UEAs that contain PEG, and COVID-19 vaccines, in particular the mRNA class of vaccines that have compositional similarity to lipid-stabilized UEAs. The mRNA in these vaccines is complexed with PEGylated cationic lipids which reduce endonuclease digestion, promote cellular uptake by antigen-presenting cells, and increase translation. The UEAs and the vaccines studied differ in their specific amphipathic lipid moieties, net charge, molar amount of PEG, and whether PEG is incorporated into the lipid membrane. Yet all of them have the potential to stimulate complement activation and CARPA through "non-self" recognition, and to sensitize for type-I hypersensitivity to PEG through adaptive immunity. 2, 7 This study surveyed for AEs that occurred early after COVID-19 vaccination in subjects who previously received lipid-stabilized UEAs. A greater proportion of vaccine-related AEs were experienced in subjects who also had AEs to UEAs, indicating a modest pattern of cross-reactivity. An important caveat is that our data have not investigated the opposite order of exposure, namely whether those with unexpected AEs to COVID-19 vaccine reactions are more susceptible to UEA reactions. One limitation of our analysis is the inability to confidently differentiate CARPA from type I hypersensitivity reactions. We have also not established a mechanism of sensitization. The finding that vaccine reactions were most common in the few subjects receiving Johnson & Johnson vaccine, which contains neither lipids nor PEG, implies that mechanisms apart from adaptive J o u r n a l P r e -p r o o f immunity can occur. As anticipated, most of the AEs with UEA administration were classified as non-severe and were nociceptive. For vaccination-related AEs, all were classified as non-severe. Accordingly, our data do not support the idea that patients should be disqualified from receiving lipid-stabilized UEAs or mRNA vaccines in those with reactions to the other. Instead, our findings simply raise awareness that cross-reactivity is possible. While are data indicate that most crossreactions that occur are expected to be non-severe, closer monitoring after vaccine or UEA administration is probably warranted in those who have had prior AE to one or the other. Larger trials will be needed to study serious AEs which are infrequent for both classes of agents, and to test whether mRNA vaccine exposure increases likelihood of UEA reactions. J o u r n a l P r e -p r o o f The safety of Definity and Optison for ultrasound image enhancement: a retrospective analysis of 78,383 administered contrast doses Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity Microbubble persistence in the microcirculation during ischemia/reperfusion and inflammation is caused by integrin-and complement-mediated adherence to activated leukocytes Influence of microbubble surface charge on capillary transit and myocardial contrast enhancement Expert Consensus Statement from the American Society of Echocardiography on Hypersensitivity Reactions to Ultrasound Enhancing Agents in Patients with Allergy to Polyethylene Glycol Ultrasound Enhancing Agents and associated adverse reactions: a potential connection to the COVID-19 vaccines? Anaphylaxis to PEGylated liposomal echocardiogram contrast in a patient with IgE-mediated macrogol allergy